These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 24428606

  • 1. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes.
    Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG.
    Am J Respir Crit Care Med; 2014 Feb 15; 189(4):419-27. PubMed ID: 24428606
    [Abstract] [Full Text] [Related]

  • 2. Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.
    Foreman MG, Wilson C, DeMeo DL, Hersh CP, Beaty TH, Cho MH, Ziniti J, Curran-Everett D, Criner G, Hokanson JE, Brantly M, Rouhani FN, Sandhaus RA, Crapo JD, Silverman EK, Genetic Epidemiology of COPD (COPDGene) Investigators * .
    Ann Am Thorac Soc; 2017 Aug 15; 14(8):1280-1287. PubMed ID: 28380308
    [Abstract] [Full Text] [Related]

  • 3. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
    Piitulainen E, Mostafavi B, Tanash HA.
    Int J Chron Obstruct Pulmon Dis; 2017 Aug 15; 12():495-500. PubMed ID: 28203073
    [Abstract] [Full Text] [Related]

  • 4. Interactions between SERPINA1 PiMZ genotype, occupational exposure and lung function decline.
    Mehta AJ, Thun GA, Imboden M, Ferrarotti I, Keidel D, Künzli N, Kromhout H, Miedinger D, Phuleria H, Rochat T, Russi EW, Schindler C, Schwartz J, Vermeulen R, Luisetti M, Probst-Hensch N, SAPALDIA team.
    Occup Environ Med; 2014 Apr 15; 71(4):234-40. PubMed ID: 24213563
    [Abstract] [Full Text] [Related]

  • 5. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.
    Thun GA, Ferrarotti I, Imboden M, Rochat T, Gerbase M, Kronenberg F, Bridevaux PO, Zemp E, Zorzetto M, Ottaviani S, Russi EW, Luisetti M, Probst-Hensch NM.
    PLoS One; 2012 Apr 15; 7(8):e42728. PubMed ID: 22912729
    [Abstract] [Full Text] [Related]

  • 6. The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.
    Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, Barr RG, Cooper C, Couper D, Han MK, Kanner RE, Kleerup EC, Martinez FJ, Paine R, Peters SP, Pirozzi C, Rennard SI, Woodruff PG, Hoffman EA, Meyers DA, Bleecker ER, NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS).
    Am J Respir Crit Care Med; 2020 Mar 01; 201(5):540-554. PubMed ID: 31661293
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ alpha1-antitrypsin phenotype.
    Silva GE, Guerra S, Keim S, Barbee RA, Sherrill DL.
    Chest; 2008 May 01; 133(5):1095-100. PubMed ID: 18263681
    [Abstract] [Full Text] [Related]

  • 8. IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.
    Demeo DL, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK.
    Am J Respir Cell Mol Biol; 2008 Jan 01; 38(1):114-20. PubMed ID: 17690329
    [Abstract] [Full Text] [Related]

  • 9. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
    Green CE, Vayalapra S, Hampson JA, Mukherjee D, Stockley RA, Turner AM.
    Thorax; 2015 Oct 01; 70(10):939-45. PubMed ID: 26141072
    [Abstract] [Full Text] [Related]

  • 10. α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts.
    Sørheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agustí A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, Paré PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK.
    Chest; 2010 Nov 01; 138(5):1125-32. PubMed ID: 20595457
    [Abstract] [Full Text] [Related]

  • 11. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population.
    Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG.
    Ann Intern Med; 2002 Feb 19; 136(4):270-9. PubMed ID: 11848724
    [Abstract] [Full Text] [Related]

  • 12. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.
    Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG.
    Am J Respir Crit Care Med; 2020 Jul 01; 202(1):73-82. PubMed ID: 32197047
    [Abstract] [Full Text] [Related]

  • 13. Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency.
    Stockley JA, Ismail AM, Hughes SM, Edgar R, Stockley RA, Sapey E.
    Eur Respir J; 2017 Mar 01; 49(3):. PubMed ID: 28356373
    [Abstract] [Full Text] [Related]

  • 14. An association between plasma levels of α2-macroglobulin and α1-antitrypsin in PiMM and PiZZ individuals differing in COPD presentation.
    Lechowicz U, Martinez-Delgado B, Liu B, Wrenger S, Rozy A, Zdral A, DeLuca DS, Welte T, Janciauskiene S, Chorostowska-Wynimko J.
    Clin Biochem; 2024 Apr 01; 126():110736. PubMed ID: 38428450
    [Abstract] [Full Text] [Related]

  • 15. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population.
    Silva GE, Sherrill DL, Guerra S, Barbee RA.
    Chest; 2003 May 01; 123(5):1435-40. PubMed ID: 12740258
    [Abstract] [Full Text] [Related]

  • 16. Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects.
    Malerba M, Ricciardolo F, Radaeli A, Torregiani C, Ceriani L, Mori E, Bontempelli M, Tantucci C, Grassi V.
    Thorax; 2006 Feb 01; 61(2):129-33. PubMed ID: 16284217
    [Abstract] [Full Text] [Related]

  • 17. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.
    Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK.
    Thorax; 2007 Sep 01; 62(9):806-13. PubMed ID: 17389752
    [Abstract] [Full Text] [Related]

  • 18. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.
    Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, O'DONNELL WJ, Reilly JJ, Ginns L, Mentzer S, Wain J, Speizer FE.
    Am J Respir Crit Care Med; 1998 Jun 01; 157(6 Pt 1):1770-8. PubMed ID: 9620904
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values.
    Pérez-Rubio G, Jiménez-Valverde LO, Ramírez-Venegas A, Camarena Á, Sansores RH, Flores-Trujillo F, Reséndiz-Hernández JM, Falfán-Valencia R.
    Arch Bronconeumol; 2015 Feb 01; 51(2):80-85. PubMed ID: 25454901
    [Abstract] [Full Text] [Related]

  • 20. COPD in individuals with the PiMZ alpha-1 antitrypsin genotype.
    Al Ashry HS, Strange C.
    Eur Respir Rev; 2017 Dec 31; 26(146):. PubMed ID: 29070580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.